The global oncology market is expected to grow at a rate of 7.5% with top-ten companies accounting for more than one-third of the market share. Roche tops the list with three drugs in the high rankings accounting for nearly 45% of the revenues. Celgene’s Revlimid is the best selling drug also showing a 20% growth rate from 2015. Interestingly, the top 10 oncology drugs revenue in 2016 is a 13% increase from 2015’s top 10 list revealing numerous market opportunities.
Manufactured by Celegene, the drug is indicated in multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. New indications such as non-Hodgkin lymphoma (NHL) have resulted in the high growth rate. Patent protection till 2022 in Europe and 2027 in U.S. will continue to drive high sales and growth rate.
The drug ranks second in the list owing to its wide spread use in colorectal cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, renal cell carcinoma and glioblastoma. The drug continues to grow strongly in the international market especially China post its approval of the lung cancer indication in 2015. However this was offbeat by the Sales in the U.S., where Avastin is already broadly used in its approved indications.
It is another block buster from the Oncology giant – Roche. The drug is used to treat early and advanced breast cancer along with gastric cancer. Sales were up 4%, aided by additional reimbursement approvals in China and continued growth in the U.S. due to longer duration of treatment in combination with Perjeta.
This product is indicated in common forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Increasing demand was observed in China, the U.Ss and Europe. Growth in China was supported by expanded regional access, largely in diffuse large B-cell lymphoma. It is one of the most vulnerable drugs of Roche due to its patent expiration by the end of 2017 in Europe and in the U.S. after 2019.
Very strong growth of the drug can be attributed to the strong uptake across all tumor types. It is indicated mostly for non-small cell lung cancer, metastatic melanoma, renal cell carcinoma and classical Hodgkin lymphoma. U.S. and international revenues increased exponentially due to higher demand resulting from the rapid commercial acceptance for several indications including melanoma, head and neck, lung, kidney and blood cancer.
The noticeable decline in the sales of this product from Novartis is due to generic competition in the U.S., Japan and certain EU countries for most of 2016. In the remaining EU countries certain intellectual property rights expired in December 2016, and generic competition there has begun. This may further result in the declining of the sales.
It is used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma, Waldenström macroglobulinemia. Imbruvica’s revenue growth is driven by increasing market share due to the currently approved indications. Global sales increased more than 100% in 2016 as a result of market share gains following the FDA and EMA approvals as a first-line treatment for patients with CLL.
Co-developed by Takeda and J&J, Velcade’s growth was negatively impacted by the generic competition. It is used to treat multiple myeloma, mantle cell lymphoma. The growth rate also slowed due to the drug’s U.S. patent expiry and invalidation in 2015.
It is used in the combination with prednisone as a treatment for metastatic castrationresistant prostate cancer. The insignificant growth can be attributed to the sales in the Asia Pacific region, primarily due to the launch in China earlier this year, was partially offset by lower sales in Europe due to competition.
Pfizer acquired Medivation in 20th 16 to expand its product portfolio with this prostate cancer drug. The company develops and commercializes Xtandi through collaboration between with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S.
Top 30 Oncology Drugs 2017last edit: 2017-09-23T08:56:38+00:00da